Brief: Aarti Drugs Says USFDA Inspected Unit's Formulations Manufacturing Facility In Himachal Pradesh
23/04/2024 07:41
April 23 (Reuters) - Aarti Drugs Ltd ADRG.NS :
* USFDA HAS INSPECTED FORMULATIONS MANUFACTURING FACILITY OF
OUR
SUBSIDIARY
* COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM
483
* NONE OF OBSERVATIONS RECEIVED ARE RELATED TO DATA
INTEGRITY
* THERE IS NO IMPACT ON FINANCIAL, OPERATION OR OTHER
ACTIVITIES
OF CO
Source text for Eikon: ID:nBSE4Tqs60
Further company coverage: ADRG.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Aarti Drugs
See all newsBrief: Aarti Drugs Says Adhish P. Patil Appointed MD For 5 Years From Oct 1
Brief: Aarti Drugs Posts June-Qtr Consol Net Profit 501.7 Million Rupees
Brief: Aarti Drugs March-Quarter Consol Profit 552.6 Million Rupees
Brief: Aarti Drugs Dividend 2 Rupees Per Share
Brief: Aarti Drugs Dec-Quarter Consol Net Profit 405.4 Million Rupees